Intraoperative Radiation Therapy Market Worth USD 66 million by 2025 (At a CAGR of 6.4%)

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.

Major Growth Drivers:

The rising incidence of cancer, technological advancements, and advantages offered by IORT over conventional radiotherapy are the major factors driving the growth of the global intraoperative radiation therapy market. Additionally, growing clinical trials exploring the use of IORT for various cancer applications is expected to offer lucrative growth opportunities to market players.

Expected Revenue Growth:

[159 Pages Report] The global intraoperative radiation therapy market is projected to reach USD 66 million by 2025 from USD 48 million in 2020, at a CAGR of 6.4% during the forecast period.

COVID-19 Impact on the global Intraoperative radiation therapy market

The intraoperative radiation therapy market was significantly impacted by the COVID-19 pandemic. Various screening, diagnostic, and surgical procedures were restricted or postponed at hospitals and cancer treatment centers, which resulted in disruptions in the cancer diagnosis as well as treatment market. The pandemic also impacted the availability of healthcare resources. Major regulatory authorities across the globe, such as the CDC, WHO, MHRA, TGA, and EMA, have identified cancer patients at a greater risk of contracting coronavirus disease than healthy adults.

Download PDF Brochure:  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=245000083

Growing global prevalence of cancer :

The IORT procedure is associated with various advantages such as targeted radiation, limited treatment time, high precision and radiation control, and minimal radiation exposure of normal tissue. This is especially true for breast cancer, as this mode offers women a choice of breast-sparing treatment (lumpectomy). The increasing prevalence of breast cancer is, therefore, a key factor driving the market growth. The growing prevalence of cancer will increase the adoption of IORT procedures. Some key statistics in this regard have been mentioned below:

  • In 2020, 276,480 new cases of invasive breast cancer and 48,530 new cases of non-invasive breast cancer were reported in the US (Source: Breastcancer.org).
  • In 2018, around 17.0 million new cases of cancer were reported worldwide; this figure is expected to reach 27.5 million by 2040 (Source: International Agency for Research on Cancer).
  • According to the American Cancer Society, in 2018, around 1.8 million new cases of cancer were diagnosed in the US.

By product & service, the product segment is expected to be the largest contributor to the intraoperative radiation therapy market

On the basis of product & service, the intraoperative radiation therapy market is segmented into IORT products and services. In 2019, the products segment is expected to account for the largest market share. The larger share of this segment can be attributed to their growing availability; development of technologically advanced mobile systems/accelerators, treatment planning, and growing applications of IORT products in cancer treatment.

By technology, the electron IORT segment is expected to grow at the highest rate during the forecast period

Based on technology, the intraoperative radiation therapy market is segmented into electron IORT and intraoperative brachytherapy. The electron IORT segment is expected to grow at the highest rate in the intraoperative radiation therapy market in 2019. The growth of this segment can be attributed to the wide range of benefits associated with it, including lesser treatment time, better depth of penetration, and optimal dose homogeneity

North America is expected to command the largest share of the Intraoperative radiation therapy market in 2019

North America, comprising the US and Canada, accounted major share of the intraoperative radiation therapy market in 2019. The major factors driving market growth in this region are the easy availability and high adoption of IORT for cancer treatment, the rising incidence of cancer, and significant per capita annual healthcare expenditure in the US and Canada. Furthermore, associations such as the American Society for Radiation Oncology (ASTRO) have advocated the use of low-energy IORT, which has contributed to its increased adoption in North America..

Request Sample Report:  https://www.marketsandmarkets.com/requestsampleNew.asp?id=245000083

Key Market Players :

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.

Major Growth Drivers:

The rising incidence of cancer, technological advancements, and advantages offered by IORT over conventional radiotherapy are the major factors driving the growth of the global intraoperative radiation therapy market. Additionally, growing clinical trials exploring the use of IORT for various cancer applications is expected to offer lucrative growth opportunities to market players.

Expected Revenue Growth:

[159 Pages Report] The global intraoperative radiation therapy market is projected to reach USD 66 million by 2025 from USD 48 million in 2020, at a CAGR of 6.4% during the forecast period.

COVID-19 Impact on the global Intraoperative radiation therapy market

The intraoperative radiation therapy market was significantly impacted by the COVID-19 pandemic. Various screening, diagnostic, and surgical procedures were restricted or postponed at hospitals and cancer treatment centers, which resulted in disruptions in the cancer diagnosis as well as treatment market. The pandemic also impacted the availability of healthcare resources. Major regulatory authorities across the globe, such as the CDC, WHO, MHRA, TGA, and EMA, have identified cancer patients at a greater risk of contracting coronavirus disease than healthy adults.

Download PDF Brochure:  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=245000083

Growing global prevalence of cancer :

The IORT procedure is associated with various advantages such as targeted radiation, limited treatment time, high precision and radiation control, and minimal radiation exposure of normal tissue. This is especially true for breast cancer, as this mode offers women a choice of breast-sparing treatment (lumpectomy). The increasing prevalence of breast cancer is, therefore, a key factor driving the market growth. The growing prevalence of cancer will increase the adoption of IORT procedures. Some key statistics in this regard have been mentioned below:

  • In 2020, 276,480 new cases of invasive breast cancer and 48,530 new cases of non-invasive breast cancer were reported in the US (Source: Breastcancer.org).
  • In 2018, around 17.0 million new cases of cancer were reported worldwide; this figure is expected to reach 27.5 million by 2040 (Source: International Agency for Research on Cancer).
  • According to the American Cancer Society, in 2018, around 1.8 million new cases of cancer were diagnosed in the US.

By product & service, the product segment is expected to be the largest contributor to the intraoperative radiation therapy market

On the basis of product & service, the intraoperative radiation therapy market is segmented into IORT products and services. In 2019, the products segment is expected to account for the largest market share. The larger share of this segment can be attributed to their growing availability; development of technologically advanced mobile systems/accelerators, treatment planning, and growing applications of IORT products in cancer treatment.

By technology, the electron IORT segment is expected to grow at the highest rate during the forecast period

Based on technology, the intraoperative radiation therapy market is segmented into electron IORT and intraoperative brachytherapy. The electron IORT segment is expected to grow at the highest rate in the intraoperative radiation therapy market in 2019. The growth of this segment can be attributed to the wide range of benefits associated with it, including lesser treatment time, better depth of penetration, and optimal dose homogeneity

North America is expected to command the largest share of the Intraoperative radiation therapy market in 2019

North America, comprising the US and Canada, accounted major share of the intraoperative radiation therapy market in 2019. The major factors driving market growth in this region are the easy availability and high adoption of IORT for cancer treatment, the rising incidence of cancer, and significant per capita annual healthcare expenditure in the US and Canada. Furthermore, associations such as the American Society for Radiation Oncology (ASTRO) have advocated the use of low-energy IORT, which has contributed to its increased adoption in North America..

Request Sample Report:  https://www.marketsandmarkets.com/requestsampleNew.asp?id=245000083

Key Market Players :

The major players in the Intraoperative radiation therapy market are ZEISS Group (Germany), iCAD, Inc. (US), Eckert & Ziegler (Germany), Elekta AB (Sweden), GMV Innovating Solutions (Spain), Sensus Healthcare, Inc. (US), IntraOp Medical, Inc. (US), Isoray, Inc. (US), Becton, Dickinson and Company (US), Sordina IORT Technologies (Italy), Varian Medical Systems, Inc. (US), SeeDos Ltd. (UK), IsoAid LLC (US), Ariane Medical Systems Ltd. (UK), Panacea Medical Technologies Pvt. Ltd. (India), Salutaris Medical Devices (US), Brainlab AG (Germany), RaySearch Laboratories (Sweden), REMEDI Co., Ltd. (South Korea), Merit Medical Systems, Inc. (US), among others.

Key Market Players :

The major players in the Intraoperative radiation therapy market are ZEISS Group (Germany), iCAD, Inc. (US), Eckert & Ziegler (Germany), Elekta AB (Sweden), GMV Innovating Solutions (Spain), Sensus Healthcare, Inc. (US), IntraOp Medical, Inc. (US), Isoray, Inc. (US), Becton, Dickinson and Company (US), Sordina IORT Technologies (Italy), Varian Medical Systems, Inc. (US), SeeDos Ltd. (UK), IsoAid LLC (US), Ariane Medical Systems Ltd. (UK), Panacea Medical Technologies Pvt. Ltd. (India), Salutaris Medical Devices (US), Brainlab AG (Germany), RaySearch Laboratories (Sweden), REMEDI Co., Ltd. (South Korea), Merit Medical Systems, Inc. (US), among others.